﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Medical Journal of Tabriz University of Medical Sciences</JournalTitle>
      <Issn>2783-2031</Issn>
      <Volume>39</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2017</Year>
        <Month>04</Month>
        <DAY>05</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Immunohistochemical study of COX-2 in melanocytic skin lesions</ArticleTitle>
    <FirstPage>38</FirstPage>
    <LastPage>43</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Effat</FirstName>
        <LastName>Khodaeiani</LastName>
      </Author>
      <Author>
        <FirstName>Ashraf</FirstName>
        <LastName>Fakhrjou</LastName>
      </Author>
      <Author>
        <FirstName>Armaghan</FirstName>
        <LastName>Ghareaghaji Zare</LastName>
      </Author>
      <Author>
        <FirstName>Shahla</FirstName>
        <LastName>Talghini</LastName>
      </Author>
      <Author>
        <FirstName>Mehdi</FirstName>
        <LastName>Amirnia</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">
      </ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2017</Year>
        <Month>02</Month>
        <Day>26</Day>
      </PubDate>
    </History>
    <Abstract>Background: cyclooxygenase-2 (cox-2) is involved in pathogenesis of various tumors and possibly malignant skin tumors including malignant melanoma; however, there is not enough information about cox-2 expression in benign melanocytic lesions. In the present study we compared the expression levels of cox-2 in malignant melanoma and benign melanocytic lesions. Methods: In this analytical study, 42 malignant melanoma from all 4 subtypes and 38 benign melanocytic lesions including dysplastic nevus, Spitz nevus and atypical nevus were evaluated for cox-2 expression using immunohistochemistry staining and intensity of cell staining (quantitatively and qualitatively). Results: Malignant melanoma compared to benign melanocytic lesions had significantly higher levels of staining (p&lt;0.001), and much more intense coloration (p&lt;0.001) and higher overall staining score (p&lt;0.001). Regarding the cox-2 staining between malignant melanoma subtypes, all four subtypes mostly had staining intensity over 60%. Also in terms of quality, the most intense staining was in the ALM, and LM and NM had moderate staining intensity. With increasing depth of involvement, cox-2 staining increases. Intensity of cell staining was also higher in cases with tumor depth of 2-4 mm. Conclusion: The results indicate the effectiveness of cox-2 in differentiating between malignant melanoma and benign melanocytic lesions. cox-2 expression correlated with the depth of invasion. Although cox-2 alone cannot be used to differentiate melanoma from benign lesions, it can be helpful in combination with other methods, in determining the prognosis and future targeted therapies.</Abstract>
  </Article>
</ArticleSet>